ADAPT
DEAD

Serial Number

90867247

Owner

EpicentRx, Inc.

Attorney

Jennifer Lee Taylor

Filing Date

Aug 5, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ADAPT Trademark

Serial Number: 90867247

ADAPT is a trademark filed by EpicentRx, Inc. on August 5, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

EpicentRx, Inc. (3 trademarks)

11099 North Torrey Pines Road, Suite 160
La Jolla, CA 92037

Entity Type: 03

Trademark Details

Filing Date

August 5, 2021

Registration Date

Not Registered

Goods & Services

Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 9, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 9, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 9, 2023 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 25, 2022 GNFN
FINAL REFUSAL E-MAILED
Oct 25, 2022 GNFR
FINAL REFUSAL WRITTEN
Oct 25, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 22, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2021 NWOS
NEW APPLICATION ENTERED
Aug 9, 2021 NWAP